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SCIENTIFIC OPINION  
Scientific Opinion on Flavouring Group Evaluation 218, Revision 1 
(FGE.218Rev1): 
alpha,beta-Unsaturated aldehydes and precursors from subgroup 4.2 of 
FGE.19: Furfural derivatives.1 
EFSA Panel on Food Contact Materials, Enzymes, Flavourings and Processing Aids 
(CEF)2, 3  
 
SUMMARY  
The European Food Safety Authority (EFSA) asked the Panel on Food Contact Materials, Enzymes, 
Flavourings and Processing Aids (the Panel) to provide scientific advice to the Commission on the 
implications for human health of chemically defined flavouring substances used in or on foodstuffs in 
the Member States. In particular, the Panel was requested to evaluate flavouring substances using the 
Procedure as referred to in the Commission Regulation (EC) No 1565/2000.  
In the present revision of FGE.218, FGE.218Rev1, there has been a reassessment of one candidate 
substance, 5-methylfurfural [FL-no: 13.001], for which there was a request for genotoxicity data in 
FGE.218. 
Flavouring Group Evaluation 218 (FGE.218) consists of furfural [FL-no: 13.018] and seven 
substances structurally related to furfural, 5-methylfurfural [FL-no: 13.001], furfuryl alcohol [FL-no: 
13.019] and five esters of furfuryl alcohol and aliphatic saturated carboxylic acids [FL-no: 13.057, 
13.062, 13.067, 13.068 and 13.128].  
In the previous version of this Opinion, FGE.218, the Panel had expressed the following view.  
                                                     
 
1  On request from the Commission, Question No EFSA-Q-2009-01083, adopted on 30 September 2010. 
2  Panel members Arturo Anadon, Mona-Lise Binderup, Wilfried Bursch, Laurence Castle, Riccardo Crebelli, Karl-Heinz 
Engel, Roland Franz, Nathalie Gontard, Thomas Haertle, Trine Husøy, Klaus-Dieter Jany, Catherine Leclercq, Jean 
Claude Lhuguenot, Wim Mennes, Maria Rosaria Milana, Karla Pfaff, Kettil Svensson, Fidel Toldra, Rosemary Waring, 
Detlef Wölfle. Correspondence: cef-unit@efsa.europa.eu  
3  Acknowledgement: The Panel wishes to thank the members of the Working Groups on Flavourings for the preparation of 
this Opinion: Ulla Beckman Sundh, Vibe Beltoft, Wilfried Bursch, Angelo Carere, Karl-Heinz Engel, Henrik Frandsen, 
Rainer Gürtler, Frances Hill, Trine Husøy, John Christian Larsen, Pia Lund, Wim Mennes, Gerard Mulder, Karin Nørby, 
Gerard Pascal, Iona Pratt, Gerrit Speijers, Harriet Wallin and EFSA’s staff members Anna Frederica Castoldi and Kim 
Rygaard Nielsen for the preparatory work on this scientific Opinion. 
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The five furfuryl esters are anticipated to be hydrolysed to furfuryl alcohol (and carboxylic acids). 
Furfuryl alcohol is expected to be oxidised to the alpha,beta-unsaturated aldehyde furfural. However, 
based on the data then available the Panel concluded that furfural is not of concern with respect to 
genotoxicity. Furthermore, the Panel concluded that not only furfural but also the structurally related 
furfuryl alcohol and the five furfuryl esters are not of concern with respect to genotoxicity. 
Accordingly these seven substances can be evaluated through the Procedure in FGE.66.  
In the FGE.218 Opinion of 2008 the Panel also expressed its view on 5-hydroxymethylfurfural and 5-
methylfurfural. It is anticipated that 5-methylfurfural [FL-no: 13.001] can be oxidised to the primary 
alcohol 5-hydroxymethylfurfural [FL-no: 13.139]. 5-Hydroxymethylfurfural has been evaluated by 
EFSA in FGE.13 dealing with furfuryl and furan derivatives. In the latter Opinion, it was concluded 
that since 5-hydroxymethylfurfural may be metabolised to 5-[(sulphoxy)methyl]furfural which shows 
genotoxic potential in vitro, 5-hydroxymethylfurfural could not be evaluated through the Procedure. 
Accordingly, the Panel concluded that 5-methylfurfural could not be evaluated through the Procedure 
either. 
Industry has submitted additional data on the 5-hydroxymethylfurfural including metabolism, 
genotoxicity and carcinogenicity data. Based on these data and further genotoxicity studies identified 
by EFSA, the Panel concluded that, notwithstanding the indications of in vitro genotoxicity in 
conditions that favour the formation of 5-[(sulphoxy)methyl]furfural and the limited in vivo 
genotoxicity study, the essentially negative results of the carcinogenicity study in rats and mice 
indicate that 5-hydroxymethylfurfural is of no concern under the conditions of intended use. This 
conclusion is also applicable to 5-methylfurfural, a candidate substance in the current FGE.218Rev1, 
because this substance may be metabolised to 5-hydroxymethylfurfural. Accordingly, both 5-
hydroxymethylfurfural [FL no: 13.001] and 5-methylfurfural [FL-no: 13.139] can be evaluated 
through the Procedure. 
© European Food Safety Authority, 2011  
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BACKGROUND 
Regulation (EC) No 2232/96 of the European Parliament and the Council (EC, 1996a) lays down a 
Procedure for the establishment of a list of flavouring substances the use of which will be authorised 
to the exclusion of all other substances in the EU. In application of that Regulation, a Register of 
flavouring substances used in or on foodstuffs in the Member States was adopted by Commission 
Decision 1999/217/EC (EC, 1999a), as last amended by Commission Decision 2009/163/EC (EC, 
2009a). Each flavouring substance is attributed a FLAVIS-number (FL-number) and all substances are 
divided into 34 chemical groups. Substances within a group should have some metabolic and 
biological behaviour in common. 
Substances which are listed in the Register are to be evaluated according to the evaluation programme 
laid down in Commission Regulation (EC) No 1565/2000 (EC, 2000a), which is broadly based on the 
Opinion of the Scientific Committee on Food (SCF, 1999a). For the submission of data by the 
manufacturer, deadlines have been established by Commission Regulation (EC) No 622/2002 (EC, 
2002b).  
After the completion of the evaluation programme the Union List of flavouring substances for use in 
or on foods in the EU shall be adopted (Article 5 (1) of Regulation (EC) No 2232/96) (EC, 1996a). 
TERMS OF REFERENCE 
The European Food Safety Authority (EFSA) is requested to carry out a risk assessment on flavouring 
substances in the Register prior to their authorisation and inclusion in a Union List according to 
Commission Regulation (EC) No 1565/2000 (EC, 2000a).  
In addition, in a letter of 11 September 2009 the Commission requested EFSA to carry out a re-
evaluation of 5-methylfurfural [FL-no: 13.001] in accordance with Commission Regulation (EC) No 
1565/2000 (EC, 2000a), if possible by the end of the evaluation programme, if not, within nine month 
from the finalisation of that programme. The deadline of the Terms of Reference was negotiated to 30 
November 2010.  
HISTORY OF THE EVALUATION OF THE SUBSTANCES IN THE PRESENT FGE 
EFSA has considered a group of furfural and seven furfural derivatives. The eight substances have 
been evaluated by the JECFA at their 55th meeting (JECFA, 2001a). 
 
FGE Adopted  Link No. of 
Candidate 
Substances 
FGE.218 9 July 2008 http://www.efsa.europa.eu/EFSA/efsa_locale-
1178620753812_1211902310134.htm
8 
FGE.218Rev1   8 
 
In the present revision of FGE.218, FGE.218Rev1, there has been a reassessment of one candidate 
substance, 5-methylfurfural [FL-no: 13.001], for which there was a request for genotoxicity data in 
FGE.218. The additional genotoxicity data submitted by Industry is on a structurally related substance, 
5-hydroxymethylfurfural [FL-no: 13.139] evaluated in FGE.13 (EFSA, 2005c). These new data are 
described, evaluated and discussed in Section 4 of the present version of FGE.218. 
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ASSESSMENT 
1. Presentation of the Substances in Flavouring Group Evaluation 218 
1.1. Description 
The present Flavouring Group Evaluation (FGE) concerns eight flavouring substances, furfural, 5-
methylfurfural,  furfuryl alcohol and five furfuryl esters which all are alpha,beta-unsaturated 
aldehydes or precursors for alpha,beta-unsaturated aldehydes, corresponding to subgroup 4.2 of 
FGE.19 (EFSA, 2008b). 
The alpha,beta-unsaturated aldehyde and ketone structures are considered by the Panel to be structural 
alerts for genotoxicity (EFSA, 2008b), and accordingly these eight substances [FL-no: 13.001, 13.018, 
13.019, 13.057, 13.062, 13.067, 13.068 and 13.128] will be considered in this FGE, especially with 
respect to the available data on genotoxic or carcinogenic activity. 
In the evaluation of the genotoxic potential of the substances in FGE.218, the Panel has taken into 
consideration the Opinion of the Scientific Committee on Food (SCF) on furfural and furfural 
diethylacetal expressed in December 2002 (SCF, 2003a). In its later updated version of Opinion of 
June 2004 (EFSA, 2004c), EFSA considered additional data on the potential genotoxicity of furfural 
which was not available at the time of the SCF Opinion. Furthermore, the Panel took into account the 
evaluation by the joint FAO/WHO Expert Committee on Food Additives (the JECFA) on furfural and 
furfuryl alcohol and related flavouring substances at its 55th meeting (JECFA, 2001b). 
The eight substances under consideration in the present evaluation are listed in Table 1 and a summary 
of their current evaluation status by JECFA is given in Table 2. 
2. Toxicity 
Genotoxicity and carcinogenicity studies from FGE.218 are summarised in Tables 3, 4, 5 and 6. 
Additional genotoxicity data are summarised in Table 7 and 8. 
2.1. Genotoxicity / Carcinogenicity - Text Taken from the SCF Opinion on Furfural and 
Furfural Diethylacetal (SCF, 2003a) 
2.1.1. Carcinogenicity Studies 
“In a two-year study in B6C3F1 mice, 50 animals of each sex received doses of 0, 50, 100 or 175 
mg/kg bw by gavage in corn oil on five days per week. At termination, there was no significant effect 
of furfural on body weight or survival. Histological examination showed chronic inflammation, 
necrosis and pigmentation in the liver of males in the two highest dose groups and in females of the 
top dose group only. Hepatocellular adenomas and carcinomas were observed in all dose groups, 
including controls but these tumours occurred with significantly increased incidence only in males of 
the top dose group. The incidence of carcinomas was similar in high dose females and controls. 
Tumours of other organs occurred only with low incidence and with no dose response relationship. 
Slight increases in the incidence of hyperplasia and papillomas in the forestomach of female mice 
were considered by the authors to be due to the irritating effect of gavage administration and not of 
toxicological significance; none of the animals had malignant lesions of the forestomach (NTP, 
1990a). 
In a similar study in Fischer 344/N rats, furfural was administered at doses of 0, 30 or 60 mg/kg bw by 
gavage in corn oil to 50 animals of each sex. Mild centrilobular hepatocellular necrosis occurred in all 
groups but the incidence did not appear to be dose related, particularly in females where the incidence 
Flavouring Group Evaluation 218, Revision1
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was inversely related to dose. Bile duct hyperplasia occurred with high incidence in all groups, 
including controls and did not appear to be treatment related. Focal bile duct dysplasia was seen in one 
male at the intermediate dose level and bile duct hyperplasia accompanied by fibrosis occurred in two 
males in the top dose group. One control male had a hepatocellular adenoma and two males in the high 
dose group had a cholangiocarcinoma (a rare tumour in historical controls). It was considered by the 
authors that although the incidence of this lesion was not statistically significant it offered some 
evidence of carcinogenicity (NTP, 1990a).” 
2.1.2. Genotoxicity Studies 
“Negative or weakly positive results have been obtained for most bacterial tests for genotoxicity. In 
particular, positive results were obtained in three out of several assays for reverse mutation in 
Salmonella typhimurium at relatively high concentrations in the absence of metabolic activation. 
Furfural was found to be clearly genotoxic in cultured mammalian cells at the gene and chromosome 
level in the absence of metabolic activation. It induced SCE in cultured CHO cells and human 
lymphocytes. It was genotoxic in Drosophila in somatic cells (Wing spot test by inhalation) and germ 
cells (sex-chromosome loss by injection). It did not induce reciprocal translocations and sex-linked 
recessive lethal mutations, with only a doubtful increase in one study in Drosophila. Furfural was not 
genotoxic in any in vivo mammalian assays for chromosome aberrations, SCE or UDS.”  
2.1.3. Conclusion 
“The Committee was of the opinion that the data were not totally convincing in demonstrating that the 
carcinogenicity of furfural was mediated via a thresholded mechanism and hence was unable to 
allocate an ADI to furfural at the present time. It was aware that a study in transgenic mice of the 
potential of furfural to induce gene mutations in vivo was in progress. The results were expected to be 
available in the near future and the Committee would wish to re-evaluate furfural in the light of the 
results of this study.” 
2.2. Genotoxicity / Carcinogenicity (Text Taken from the EFSA Opinion on Furfural and 
Furfural Diethylacetal (EFSA, 2004c) 
2.2.1. Genotoxicity 
“In a new study not previously evaluated by the SCF, furfural was examined for its potential to induce 
gene mutations of the λlacZ-gene in vivo in the liver of male transgenic mice (CD2F1(BALB/c x 
DBA/2) strain 40.6, with lacZ-genes as reporter genes). The study was carried out under GLP. As 
formal technical guidelines for this type of study are not available, the study protocol was designed in 
conformity with principles for transgenic studies identified by international expert groups (Gorelick & 
Mirsalis, 1996; Heddle et al., 2000). The study was conducted in five groups, three of which received 
furfural by gavage in corn oil, one negative control group received vehicle alone and one positive 
control group received ethylnitrosourea (ENU). The furfural and negative control groups each 
comprised 13 mice plus 2 back-up animals; the positive control group comprised 8 mice plus 2 
reserves. The furfural groups were given doses of 75, 150 or 300 mg furfural/kg bw in corn oil by 
gavage for 28 consecutive days; ENU was given to the positive control group by intraperitoneal 
injection in saline on days 5-9 of the study at a dose of 50 mg/kg bw/day. On day 28, three animals 
from each of the furfural and negative control groups were sacrificed for assessment of hepatotoxicity 
by clinical chemistry and histological examination. In addition, organ and body weights were 
monitored throughout. After a manifestation period of 34-35 days (days 62-63 of the study), the livers 
and samples of gastrointestinal tract tissues were fixed for mutation analysis. Mutation analysis was 
carried out on livers of eight animals per group. At least 5000 (preferably 120,000) plaque-forming 
units (PFU) were examined (one PFU corresponding to one recovered copy of the λgt10lacZ shuttle 
vector).  
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There were three early decedents in the highest furfural dose group; two during treatment with no 
clinical signs, and one during the manifestation period. One animal from the low-dose group died 
during the manifestation period. The cause of death could not be ascertained.  
Body weights in the furfural-treated groups showed a dose related increase compared to negative 
controls during the first week of treatment. In the post-treatment period the difference between control 
and two lower dose groups disappeared but the body weight of the group treated with 300 mg 
furfural/kg bw remained higher.  
Evaluation of the clinical chemistry and gross and histopathology of the liver of the treated animals 
sacrificed at the end of the treatment period showed an increase in blood triglycerides, increased liver 
weight and centrilobular hypertrophy. This was interpreted by the authors as some evidence of 
hepatotoxicity. These changes did not persist until the end of the manifestation period, 34-35 days 
after the last dose.  
The mutation frequency in DNA extracted from the livers of the negative control group was similar to 
historical data. There was no significant difference in mutation frequency between negative controls 
and the furfural-treated groups; the positive control group showed a significant increase in mutation 
frequency. It was concluded that oral administration of furfural in corn oil at levels of up to 300 mg/kg 
bw/day is not associated with an increase in the induction of mutations in liver cells of λlacZ 
transgenic mice (CIVO-TNO, 2003).  
Negative or weakly positive results have been obtained for most bacterial tests for genotoxicity. In 
particular, positive results were obtained in three out of several assays for reverse mutation in 
Salmonella typhimurium at relatively high concentrations in the absence of metabolic activation. 
Furfural was found to be clearly genotoxic in cultured mammalian cells at the gene and chromosome 
level in the absence of metabolic activation. It induced Sister Chromatid Exchange (SCE) in cultured 
Chinese Hamster Ovary (CHO) cells and human lymphocytes. It was genotoxic in Drosophila in 
somatic cells (Wing spot test by inhalation) and germ cells (sex-chromosome loss by injection). It did 
not induce reciprocal translocations and sex-linked recessive lethal mutations, with only a doubtful 
increase in one study in Drosophila. Furfural was not genotoxic in any in vivo mammalian assays for 
chromosome aberrations, SCE or Unscheduled DNA Synthesis (UDS) and the study in transgenic 
mice confirms that furfural does not induce gene mutations in vivo.” 
2.2.2. Discussion 
“The Panel noted the metabolic and toxicity data previously reviewed by the SCF together with the 
new results of the genotoxicity study in transgenic mice in vivo.  
Furfural was negative in the in vivo genotoxicity assay and this corroborated earlier negative in vivo 
studies at the chromosome level and in a UDS assay.  
In view of the absence of genotoxicity in vivo, the tumours observed in the long-term 
toxicity/carcinogenicity studies in male, but not female mice, are considered to arise as a consequence 
of chronic hepatotoxicity (hepatocellular necrosis) which was more marked in male animals. An 
increased tumour incidence was only observed at the highest dose level and at a dose higher than the 
minimal hepatotoxic dose.  
It should be noted that no hepatocellular tumours were seen in the long-term rat study. However, liver 
toxicity was seen in this study (see SCF Opinion, Appendix 1) and the rat was considered more 
sensitive to liver toxicity. The hepatotoxicity of furfural is dose-dependent but a NOEL was not 
established in the long-term studies. However, the short-term (90-day) study in rats was conducted to 
establish a NOEL for hepatotoxicity, which was determined to be 54 mg/kg bw The Panel noted that 
because of possible formulation (corn oil) and dose regimen (bolus dose) effects observed in the 
gavage studies, the dietary administration studies were more appropriate for identifying a NOAEL. 
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The Panel concluded that the NOAEL of 54 mg/kg bw/day for hepatic changes from the 90 day 
dietary study was appropriate and noted that the effects observed with doses up to threefold higher 
were of doubtful toxicological relevance. Therefore the Panel concluded that a safety factor of 100 
would be sufficient in establishing an ADI from this subchronic study (see SCF Opinion).” 
2.2.3. Conclusion and Recommendation 
“The Panel concluded that furfural did not exhibit genotoxicity in vivo in male mice, the species and 
sex which displayed an increased tumour incidence in long-term studies and that the tumours arose by 
a secondary mechanism consequent on hepatotoxicity, which is dose dependent, displays a threshold 
and is seen in both rats and mice. It was therefore considered that the NOEL for hepatotoxicity in the 
rat could be used to derive an ADI for furfural.  
An ADI for furfural was established at 0.5 mg/kg bw based on the NOEL of 54 mg/kg bw from the 
90-day rat study to which a 100 fold safety factor was applied. Since furfural diethylacetal is rapidly 
converted to furfural at physiological pH, the ADI applies also to the furfural component of furfural 
diethylacetal since furfural is readily liberated from the acetal in vivo.” 
2.3. EFSA Remark on Carcinogenicity Studies 
The hepatocellular tumours induced in B6C3F1 mice in the NTP study (NTP, 1990a) are not 
considered relevant for humans. Indeed, it was clearly demonstrated that such tumours arise in this 
strain of mice, which is highly susceptible to hepatocarcinogenicity due to the presence of various 
strain-species-specific genes (hcs). Thus, the study does not give rise to concern with respect to 
carcinogenicity in humans. 
2.4. EFSA Remark on Genotoxicity of 5-Hydroxymethylfurfural – Text taken from 
FGE.2184 (EFSA, 2009s) 
“It is anticipated that 5-methylfurfural [FL-no: 13.001] can be oxidised to the primary alcohol 5-
hydroxymethylfurfural [FL-no: 13.139]. 5-Hydryxymethylfurfural was evaluated by EFSA in FGE.13 
dealing with furfuryl and furan derivatives (EFSA, 2005c). As 5-hydroxymethylfurfural may be 
metabolised to 5-[(sulphoxy)methyl]furfural which shows genotoxic potential in vitro, it was 
concluded that 5-hydroxymethylfurfural could not be evaluated through the Procedure (EFSA, 2005c). 
Accordingly 5-methylfurfural cannot be evaluated through the Procedure either.” 
2.5. Genotoxicity of Furfuryl Alcohol and Related Substances - Text Taken from JECFA 
(JECFA, 2001b) 
No genotoxicity text was prepared by JECFA on the group of furfuryl alcohol and related substances – 
the studies are only given in table format (see Table 4). 
One of the substances in the group of furfuryl alcohol and related substances is furfural [FL-no: 
13.018], which also was considered separately at the 55th JECFA meeting where the following was 
stated: 
“Furfural was evaluated previously by the Committee at its thirty-ninth and fifty-first meetings 
(JECFA, 1992a; JECFA, 2000a). An ADI was not established at either meeting because of concern 
about the finding of tumours in male mice given furfural in corn oil by gavage and the fact that no 
NOEL was identified for hepatotoxicity in male rats. In a study in mice, the combined incidence of 
                                                     
 
4 The conclusion in section 2.4 is cited from the previous version of the present FGE, FGE.218. This conclusion 
is the basis for the request of additional genotoxicitydata in FGE.218. 
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adenomas and carcinomas was increased in males at the highest dose (175 mg/kg bw per day). In order 
to address its concern with regard to the formation of liver tumours in mice, the Committee at its fifty-
first meeting requested the results of studies of DNA binding or adduct formation in vivo to clarify 
whether furfural interacts with DNA in the liver of mice, and also requested the results of a 90-day 
toxicity study in rats to identify a NOEL for hepatotoxicity (Annex 1, reference 137). 
Since the last meeting, the results of a 14-day study to determine a dose range, a 90-day study of 
toxicity in rats, and an assay for unscheduled DNA synthesis in mice in vivo have become available. 
These data were reviewed and are summarised in the following monograph addendum.” 
 “The ability of furfural to induce DNA repair in the hepatocytes of B6C3F1 mice was assessed in an 
assay for unscheduled DNA synthesis. The maximum tolerated dose for animals of each sex was 
determined in a preliminary study to be 320 mg/kg bw. In the study of unscheduled DNA synthesis, 
doses of 50, 175, and 320 mg/kg bw were given to groups of three animals of each sex, and expression 
of DNA repair was measured 2–4 and 12–16 hours after treatment. N-Nitrosodimethylamine (20 
mg/kg bw) was used to measure expression within 2–4 hours and aminoazotoluene (200 mg/kg bw) 
for expression within 12–16 hours, as positive controls. 
The animals treated with furfural did not show increased UDS at either time after dosing, whereas the 
positive controls showed statistically significant increases in net nuclear grain counts. Little replicative 
DNA synthesis (0–0.4 %) was seen at either interval. The results provided no evidence that furfural 
damages DNA in mouse hepatocytes at doses up to 320 mg/kg bw (Edwards, 1999).” 
“The results of an assay for unscheduled DNA synthesis in mice in vivo were reviewed by the 
Committee. This study, in which doses of up to 350 mg/kg bw were given, was particularly relevant 
since it addressed potential DNA repair in the cells in which tumours arose, namely hepatocytes. The 
negative results obtained in this assay were considered by the Committee to provide evidence that the 
liver tumours observed in the long-term study in mice were unlikely to have occurred through a 
genotoxic mechanism. The Committee considered that the concerns raised previously with respect to 
the liver tumours in mice were adequately addressed by this study and that a study of DNA binding 
was unnecessary.” 
3. EFSA Conclusions on Genotoxicity of Furfuryl Alcohol and Related Substances – Text 
taken from FGE.2185 (EFSA, 2009s) 
“The present group consists of furfural [FL-no: 13.018] and seven substances structurally related to 
furfural: 5-methylfurfural [FL-no: 13.001], furfuryl alcohol [FL-no: 13.019] and five esters of furfuryl 
alcohol and aliphatic saturated carboxylic acids [FL-no: 13.057, 13.062, 13.067, 13.068 and 13.128]. 
The five furfuryl esters are anticipated to be hydrolysed to furfuryl alcohol (and carboxylic acids), 
which is expected to be oxidised to the alpha,beta-unsaturated aldehyde furfural (EFSA, 2005c). 
Based on data available the Panel has previously concluded that furfural is not of concern with respect 
to genotoxicity (EFSA, 2004c). Furthermore, the Panel concluded that not only furfural but also the 
structurally related furfuryl alcohol and the five furfuryl esters are not of concern with respect to 
genotoxicity. Accordingly, these seven substances can be evaluated through the Procedure in FGE.66.  
It is anticipated that 5-methylfurfural [FL-no: 13.001] can be oxidised to the primary alcohol 5-
hydroxymethylfurfural [FL-no: 13.139]. 5-Hydroxymethylfurfural was evaluated by EFSA in FGE.13 
dealing with furfuryl and furan derivatives (EFSA, 2005c). As 5-hydroxymethylfurfural may be 
metabolised to 5-[(sulphoxy)methyl]furfural which shows genotoxic potential in vitro, it was 
concluded that 5-hydroxymethylfurfural could not be evaluated through the Procedure. Accordingly 5-
methylfurfural cannot be evaluated through the Procedure either.” 
                                                     
 
5 The conclusion in Section 3 is cited from the previous version of the present FGE, FGE.218. This conclusion is 
the basis for the request of additional genotoxicitydata in FGE.218. 
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4. Additional Data Submitted by Industry 
4.1. Background 
As a response to the conclusions in FGE.13 (EFSA, 2005c) and FGE.218 (Adopted 9 July 2008), 
Industry has presented additional toxicology and metabolism data relevant to the safety evaluation of 
5-hydroxymethylfurfural (5-HMF) [FL-no: 13.139] and 5-methylfurfural (5-MF) [FL-no: 13.001].  
These data include:  
- the NTP (2008-draft) carcinogenicity studies in mice and rats  
- mutagenicity studies in S. typhimurium and E. coli,  
- a 3-months mouse micronucleus assay (NTP, 2008b),  
- an in vitro Comet assay (Durling et al., 2009) and  
- metabolic data in mice (NTP, 2008b).  
All of these studies have been carried out using 5-HMF as the testing substance.  
Besides the new data submitted by Industry, additional studies (Dahlberg, 2004, Glatt et al., 2005, 
Glatt and Sommer, 2006, Monien et al., 2009) have been retrieved from the public literature by EFSA. 
5-HMF has been shown to be bioactivated in vitro to 5-sulfoxy-methylfurfural (SMF) through 
sulphonation of its allylic hydroxymethyl group catalyzed by sulphotransferases (SULT). SMF can be 
transformed to a highly reactive electrophilic allyl carbocation, which can react with nucleophiles (e.g. 
DNA) producing mutagenic effects. With few exceptions, HMF was negative in most in vitro 
genotoxicity tests, very likely because the metabolic activation systems lacked SULT enzymes or the 
cofactor sulpho-group donor PAPS. 5-HMF was mutagenic in Salmonella typhimurium after addition 
of PAPS to the liver cytosol, while SMF was directly mutagenic. No in vivo genotoxicity data were 
reported in FGE 13. Even if the occurrence of the metabolic pathway through sulphonation by SULT 
enzymes in vivo cannot be ruled out, the data reported in FGE.13 (Godfrey et al., 1999) indicate that 
for 5-HMF the principal route in mice and rats is the oxidation to furoic acid, followed by conjugation 
with glycine and by rapid excretion in the urine. 
4.2. Summaries and Evaluation of Additional Data 
4.2.1. Carcinogenicity Studies 
Groups of B6C3F1 mice (50/sex/dose) were administered 0, 188, 375 or 750 mg/kg body weight (bw) 
per day of 5-HMF, five days per week for 104 weeks via aqueous gavage. Survival probabilities of 
male and female mice in the 750 mg/kg bw per day dose group were significantly lower than those of 
vehicle controls. Mean body weights of 750 mg/kg males were 14 % lower than those of the vehicle 
controls after week 26. Mean body weights of 375 and 750 mg/kg females were 9 % and 30 % lower, 
respectively, than those of the vehicle controls after week 36. Because of the reduced survival (30 % 
reduction) of the groups receiving 750 mg/kg bw per day 5-HMF, the groups of mice receiving this 
dose were not included in the evaluation of carcinogenic potential. Incidences of hepatocellular 
adenoma or carcinoma (combined) were significantly increased in the 188 and 375 mg/kg female mice 
when compared to vehicle controls, with increased incidences (about two-fold, not dose-related) of 53 
% and 52 %, respectively. No carcinogenic effect was observed in male mice (NTP, 2008b). Historical 
control data for hepatocellular adenoma in female B6C3F1 mice were: 20/50, 11/50, 8/50, 10/51, 
13/50, 12/50, 3/50, 6/50, 17/60 (Average 21.7 %) (NTP, 2008b). Survival of both males and female 
mice in the 750 mg/kg group was significantly lower than that of the vehicle control group. 
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Groups of F344/N rats (50/sex/dose) were administered 0 (vehicle control), 188, 375 and 750 mg/kg 
bw per day of 5-HMF, five days per week for 104 weeks via aqueous gavage. Survival of the 188 and 
750 mg/kg bw per day male groups was higher than that of vehicle controls and the remaining groups 
were comparable to vehicle controls. Mean body weights of all test groups were comparable to vehicle 
controls throughout the study. Males of the 188 and 375 mg/kg bw per day males showed increased 
incidences of calcitonin-producing parafollicular cell adenoma or carcinoma (combined) of the thyroid 
gland. No other carcinogenic effects were observed (NTP, 2008b). 
The NTP concluded: “Under the conditions of this 2-year gavage study, there was no evidence of 
carcinogenic activity in male or female F344/N rats administered 188, 375 or 750 mg/kg/day. There 
was no evidence of carcinogenic activity in male B6C3F1 mice administered 188 or 375 mg/kg. There 
was some evidence of carcinogenic activity of 5-(hydroxymethyl)-2-furfural in female B6C3F1 mice, 
based on increased incidences of hepatocellular adenoma in the 188 and 375 mg/kg groups.” 
According to the Panel, the about two-fold increase (not dose-related) of hepatocellular tumours 
observed in B6C3F1 female mice is not relevant for humans, in view of the recognized high genetic 
susceptibility of this strain to hepatocarcinogenesis. These studies do not give rise to concern with 
respect to the carcinogenic potential of 5-HMF. 
4.2.2. Genotoxicity Studies  
Weak mutagenic activity was reported in S. typhimurium TA100 strain in the absence of metabolic 
activation, while no mutagenicity was observed in strains TA97, TA98, TA102 and TA1535 in a range 
of concentrations of 100-10,000 micrograms/plate; however, negative results were reported in another 
study with TA98 and TA100 strain and E.coli WP2 uvrA/pKM101 in a range of concentrations of 
1,500-10,000 micrograms/plate (NTP, 2008b). 
At the end of a 3-month toxicity study, peripheral blood samples were obtained from male and female 
B6C3F1 mice receiving 0, 47, 188, 375 or 750 mg/kg bw/day of 5-HMF via gavage. Slides were 
scanned to determine the frequency of micronuclei in 1,000 normochromatic erythrocytes (NCEs) in 
10 animals per sex per treatment group. In addition, the percentage of polychromatic erythrocytes 
(PCE) in a population of 1,000 erythrocytes was determined as a measure of bone marrow toxicity. No 
increases in the frequency of micronucleated erythrocytes were observed; in addition, no significant 
dose-related changes in the percentage of immature PCE were observed, suggesting that the chemical 
did not exhibit bone marrow toxicity (NTP, 2008b). 
The DNA-damaging potential of 5-HMF was tested in vitro in the Comet assay with the following five 
cell lines with various degree of SULT1A1 expression (Durling et al., 2009):  
two human lines (Caco-2, no detectable 1A1 activity; HEK293, high 1A1 activity),  
two cell lines from Chinese hamster (V79, no detectable 1A1 activity and V79-hp-PST, high 
1A1 activity) and  
one mouse lymphoma line (L5178Y, no detectable activity).  
The cell lines were incubated with 0, 2.5, 7.5, 25, 50 or 100 mM (ca. 0, 0.3, 1.0, 3.3 6.3 or 12.6 
mg/ml) of 5-HMF for three hours and subjected to a Comet assay to assess DNA damage. DNA 
damage was observed at the highest concentration (100 mM) in all cell lines, with significant 
reduction in cell viability (from 11 to 30 %). The concentration of 100 mM is 10 times higher than the 
highest concentration (10 mM or 5000 micrograms/ml) recommended by OECD guidelines for in vitro 
testing with mammalian cells. 100 mM was the lowest effective concentration for three cell lines, 
Caco-2, HEK293 and L5178Y. In the V79 (lowest SULT1A1) and V79-hp-PST (highest SULT1A1) 
DNA damage was induced also at lower concentrations (lowest effective concentration: 25 mM or 
3193 micrograms/ml), without a reduction in cell viability. Surprisingly, the positive control (HMP, 
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0.01 mM) induced significant damage in Caco-2, V79 and V79-hp-PST cells, but not in HEK293. The 
authors (Durling et al., 2009) concluded that in all cell lines 5-HMF-induced DNA damage was 
unrelated to the expression of SULT1A1, but they mentioned that the SULT1A1 activities in these 
three cell lines (Caco-2, HEK293 and L5178Y) were much lower than those that can be found in 
human gut and liver. The possibility was left open that SULT1A1 activity was too low to efficiently 
bioactivate 5-HMF also in the cell line with highest SULT1A1 activity. In V79 cells without 
SULT1A1 activity and in V79-hp-PST with SULT1A1 activity at the same level as in human gut and 
liver, no difference in extent of DNA-damage could be observed. This would indicate absence of a 
significant contribution of sulphate conjugation in the DNA-damaging activity of 5-HMF. 
These results are in conflict with the results of Glatt et al. (Glatt et al., 2005) who reported induction of 
SCE in 5-HMF-exposed genetically modified V79 cells expressing high levels of human CYP2E1 and 
SULT1A1. They are also in contrast with the observations by Sommer et al. (2003; abstract only) 
reporting the mutagenicity of 5-HMF in a genetically modified S. typhimurium strain expressing 
human SULT1A1. According to Durling et al. (2009), the reasons of these discrepancies are unknown. 
One possibility is the different sensitivity of the Comet assay compared to other systems. Durling et al. 
(2009) concluded that other important mechanisms for the observed DNA damage should be 
investigated, but that under the conditions of the test, 5-HMF is a rather weak DNA-damaging agent. 
In a new publication by Severin et al. (2010), a dose dependent increase in DNA damage was 
observed in a Comet assay with HepG2 cells exposed to 5-HMF (0, 5.35, 7.87, 11.57, 17, 25, 36.6 
mM) for 20 hours, with a significant increase from 7.87 to 36.6 mM 5-HMF. Cytotoxicity was 
observed at the two highest doses (25 and 36.6 mM), with an estimated IC50 of 38 mM. HepG2 cells 
express both CYP and SULT enzymes. In the same publication, no effect of 5-HMF was found in an 
in vitro micronucleous assay in the same cell line exposed to similar doses of 5-HMF (20 hours). 5-
HMF was also tested in an Ames test performed according to the OECD guidelines 471. No increase 
in mutants was observed in S. typhimurium strains TA 98, TA 100, TA1535, TA 1537 exposed to 5-
HMF at 0.5 µg/mL up to 5000 µg/mL with or without metabolic activation (S9). No additional PAPS 
was added to the test system, making activation by SULT less likely (Severin et al., 2010).  
However, while 5-methylfurfural (5-HMF) was unable to induce micronuclei in vivo, in the NTP 3-
months study in mice by gavage, and in vitro, using the Hep-G2 human cell line expressing both CYP 
and SULT enzymes, its metabolite 5-sulphoxy-methylfurfural (5-SMF) has been reported to induce 
micronuclei in peripheral erythrocytes in mice (Dahlberg, 2004). 
According to Glatt and Sommer (2006), incubation of DNA with SMF in a cell-free system led to the 
formation of DNA adducts that could be detected by the 32P-postlabelling technique. No adducts were 
formed after incubations with 5-HMF instead of 5-SMF. In subsequent experiments, the authors 
searched for these adducts in mammalian and bacterial cells treated with 5-SMF and in SULT-
proficient cells treated with 5-HMF. Although mutations were induced, adducts were not seen in these 
cells under the same conditions. The authors hypothesized that the lack of DNA adducts might be due 
to technical problems, since generally DNA adducts are a more sensitive endpoint than mutations as 
observed with many other compounds (Glatt & Sommer, 2006). 
The additional available genotoxicity studies are summarised in Tables 7 and 8.  
4.2.3. New Metabolic Data  
As a part of the NTP 3-week and 3-month sub-chronic toxicity studies program, male and female 
F344/N rats and B6C3F1 mice were administered 1,500 mg/kg bw per day of 5-HMF. During this time 
the urine of the animals was collected and analyzed for the presence of metabolites. The two major 
metabolites detected were 5-(hydroxymethyl)-2-furoic acid and the corresponding glycine conjugate 
5-(Hydroxymethyl)-furoyl glycine. Continuous exposure of mice to 5-HMF showed that a 
considerably larger amount of each metabolite was excreted in the urine at day 94 as compared to day 
17. This would indicate that exposure to 5-HMF induces enzymes that facilitate oxidation to furoic 
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acid and conjugation to glycine. As expected due to its reactivity and short half-life, 5-(sulphoxy)-
methylfurfural was not detected  (see below) (NTP, 2008b). 
Monien et al. (2009) have shown that 5-(sulphoxy)-methylfurfural (5-SMF) is formed in vivo in mice. 
Twelve week-old FVB/N mice (n=28) were given an intravenous injection of 100 mg/kg bw 5-HMF 
in isotonic saline. Two blood samples were taken from each animal, and blood samples were pooled 
from different animals to study 5-HMF and 5-SMF pharmacokinetics. 5-SMF was detected in plasma 
from animals given 5-HMF, and the half-life of 5-SMF was calculated to be 4.2 minutes. It should be 
noted that 5-SMF is very hydrophilic and therefore has limited capacity to cross cell membranes and 
of entering cells. Therefore 5-SMF would be expected to induce mutation at the site of formation, i.e 
mainly within the liver cell. Based on the plasma half-life of 4.2 minutes, it is not expected that this 
metabolite could reach the bone marrow (Monien et al., 2009). 
4.3. Discussion of the newly submitted data 
Taking into account all the presently available data the following scenario emerges: 
5-HMF is negative in the conventional Ames test. Mutagenicity is observed only upon inclusion of 
PAPS, a sulpho-group donor and liver cytosol into the metabolic system, suggesting the formation of a 
sulphate-ester (5-SMF). In accordance, 5-SMF was mutagenic in the absence of any metabolic 
activation system. In an in vitro assay, 5-HMF induced dose-dependent increase in DNA damage 
(Comet assay), but this study has major drawbacks and inconsistencies that limit its validity. A major 
limit is the use of too high concentrations that can produce unpredictable effects, not related to the real 
genotoxic potential  of 5-HMF, and this is particularly true for a test like the Comet assay. 
Furthermore, as also stated by the authors, DNA damage was unrelated to the expression of SULT1A1 
activity. Also in another Comet assay in HepG2 cells, able to express both CYP and SULT enzymes, 
indications for DNA damage were observed, but the substance did not induce clastogenic or aneugenic 
effects in a micronucleus assay in the same cell system. 
In vivo, a non-standard micronucleus assay in peripheral blood erythrocytes associated to a sub-
chronic study in mice, provided no indication of a genotoxic potential, but this study has limited 
validity since no bone marrow cell toxicity was observed. 
Metabolic studies in B6C3F1 mice and rats indicate that in vivo the principal route of metabolism is 
oxidation of 5-HMF to furoic acid, followed by glycine conjugation and rapid elimination in the urine. 
However, a recent pharmacokinetic study in FVB/N mice has shown that SMF (half-life of 4.2 
minutes) has been detected in plasma from animals given 5-HMF intravenously. This indicates that 
there is a competition for the substrate 5-HMF between the oxidation pathway leading to furoic acid 
and the sulphonation pathway leading to the 5-SMF metabolite. In rodents the formation of the SMF 
metabolite is too low to result in a carcinogenic response. Assuming that the ratio between the two 
competing pathways is not more favorable for the formation of 5-SMF in humans than in rodents, no 
genotoxicity or carcinogenicity is expected in humans either. As reported in FGE.13Rev1 (EFSA, 
2009am), the limited data available in humans showed that furoylglycine and 2,5-furan dicarboxylic 
acid can be found in urine, and that these metabolites are derived from precursors in food e.g. fructose 
(Jellum et al., 1973). Thus, it can be anticipated that in humans, after oral administration, 5-HMF will 
also be rapidly converted into furoic acid derivatives which will be rapidly eliminated via the urine. 
The results of NTP long-term carcinogenicity bioassays have shown that 5-HMF is not carcinogenic in 
male and female rats, as well as in male mice. The about two-fold increase (not-dose-related) of 
hepatocellular adenomas in B6C3F1 female mice, a strain known to be genetically highly susceptible 
to liver tumours, is considered to be not relevant for humans. 
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4.4. Conclusion 
Notwithstanding the indications of in vitro genotoxicity in conditions that favour the formation of 5-
SMF and the limited in vivo genotoxicity study, the essentially negative results of the carcinogenicity 
study in rats and mice indicate therefore that 5-HMF is of no concern under the conditions of intended 
use (EFSA, 2005c). This conclusion is also applicable to 5-methylfurfural, a candidate substance in 
the current FGE, because this substance may be metabolised to 5-hydroxymethylfurfural. 
Accordingly, both 5-HMF [FL no: 13.001] and 5-MF [FL-no: 13.139] can be evaluated through the 
Procedure. 
 
Flavouring Group Evaluation 218, Revision1
 
 
15 EFSA Journal 2011; 9(3):1840 
TABLE 1: SPECIFICATION SUMMARY OF THE SUBSTANCES IN THE FLAVOURING GROUP EVALUATION 218 (JECFA, 2001B) 
Table 1: Specification Summary of the Substances in the Flavouring Group Evaluation 218 (JECFA, 2001b) 
FL-no 
JECFA-no 







Solubility in ethanol 
2) 
Boiling point, °C 3) 
Melting point, °C 
ID test 
Assay minimum 


























































































































































1) Solubility in water, if not otherwise stated. 
2) Solubility in 95 %  ethanol, if not otherwise stated. 
3) At 1013.25 hPa, if not otherwise stated. 
4) At 20°C, if not otherwise stated. 
5) At 25°C, if not otherwise stated. 
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TABLE 2: SUMMARY OF SAFETY EVALUATION APPLYING THE PROCEDURE (BASED ON INTAKES CALCULATED BY THE MSDI APPROACH) 
Table 2: Summary of Safety Evaluation Applying the Procedure as Applied by JECFA (JECFA, 2001a) 
FL-no 
JECFA-no 
EU Register name Structural formula MSDI 1) 
(μg/capita/day) 
Class 2) 
Evaluation procedure path 3) 
Outcome on the named 
compound 



















































































B3: Intake below threshold, B4: Adequate 
NOAEL exists 
4) 
1) EU MSDI: Amount added to food as flavour in (kg / year) x 10E9 / (0.1 x population in Europe (= 375 x 10E6) x 0.6 x 365)  =  µg/capita/day. 
2) Thresholds of concern: Class I = 1800, Class II = 540, Class III = 90 µg/person/day. 
3) Procedure path A substances can be predicted to be metabolised to innocuous products.  Procedure path B substances cannot. 
4) No safety concern based on intake calculated by the MSDI approach of the named compound. 
5) Data must be available on the substance or closely related substances to perform a safety evaluation. 
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TABLE 3: CARCINOGENICITY STUDIES (SCF, 2003A) 
One carcinogenicity study is available for the substances in subgroup 4.2. 
Table 3: Carcinogenicity Studies 









Rats; Male , Female 
50/sex/group 
Gavage 0, 30 and 60 mg/kg 
bw/day in corn oil for 
5 days/week 
2 year Male: Centrilobular necrosis of the liver was seen 
at increased incidences in the dosed male rats 
(control, 3/50; low dose, 9/50; high dose, 12/50. 
Two high dose males had bile duct dysplasia with 
fibrosis, and two had cholangiosarcomas. 
Female: No increases in tumour incidences 
(NTP, 1990a) The Panel agrees with the authors 
that for male rats there is some 
evidence of carcinogenic activity 
and for females no evidence of 
carcinogenic activity.  
Mice; Male, Female 
50/sex/group 
Gavage 0, 50, 100 and 175 
mg/kg bw/day in corn 
oil for 5 day/week 
2 year Male: Increased incidence of hepatocellular 
adenomas and carcinomas in the high dose group  
Female: Increased incidence of hepatocellular 
adenomas and carcinomas in the high dose group. 
Forestomach hyperplasia and squamous cell 
papillomas were increased in the high dose group. 
(NTP, 1990a) 1) 
The Panel agrees with the authors 
that for male mice there is clear 
evidence of carcinogenic activity 
and for females some evidence of 
carcinogenic activity. 
1) The Panel noted the strain/species specific susceptibility of the tested mice to hepatocarcinogenesis. These tumours are not relevant for the evaluation of carcinogenic effect for humans. 
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TABLE 4: GENOTOXICITY (IN VITRO AND IN VIVO) (JECFA, 2001B) 
Table 4: Summary of genotoxicity data of furfuryl derivatives evaluated by JECFA (JECFA, 2001b) 
FL-no 
JECFA-no 
EU Register name 
JECFA name 








Reverse mutation  S. typhimurium TA98, TA100, 
TA1535, TA1537 
294 µg/plate Negativea,b (Florin et al., 1980) 
Reverse mutation S. typhimurium TA98, TA100, 
TA1535 
Up to 10 000 µg/plate Negativea,b (Mortelmans et al., 1986) 
Reverse mutation S. typhimurium TA100 2500–12 500µg/ml  Negativea,b (Stich et al., 1981a) 
Reverse mutation S. typhimurium TA98, TA100, 
TA102 
Up to 198 000 µg/plate Negativea,b (Aeschbacher et al., 1989) 
Reverse mutation S. typhimurium TA98, TA100 81–323 µg/plate Negativea,b (Shinohara et al., 1986) 
Reverse mutation  S. typhimurium TA1535, TA100, 
TA1537 (modified assay) 
200 000 µg/ml Positivea,b (McGregor et al., 1981) 
DNA repair and H17 (rec+) B. subtilis M45 (rec–) µg/disc 2000–20 000  Positivea,b (Shinohara et al., 1986) 
Sister chromatid exchange  Chinese hamster ovary cells 245 µg/ml Positivea,b (Stich et al., 1981b) 
Sister chomatid exchange Human lymphocytes Up to 196 µg/ml Negative (Jansson et al., 1986) 
Siser chromatid exchange Human lymphocytes Up to 970 µg/ml Negative (Gomez-Arroyo & Souza, 
1985) 
Chromosomal aberration Chinese hamster ovary cells 2000 µg/ml Positive (Stich et al., 1981b) 
Gene conversion  S. cerevisiae strain D7 13 500–16 000 µg/ml Positivea (Stich et al., 1981a) 
Sex-linked recessive lethal mutation D. melanogaster 6500 ppm by injection Negative (Rodriquez-Arnaiz et al., 
1989) 
Sister chromatid exchange Adult human lymphocytes 32 300 mg/m3 in occupational 
atmosphere 
Negative (Gomez-Arroyo & Souza, 
1985) 
Sister chomatid exchange Adult human lymphocytes 32 300 mg/m3 in occupational 
atmosphere 




Mouse bone marrow cells  
  
0.5 mg/kg bw in drinking 
water 












Reverse mutation S. typhimurium TA1535, TA98, 
TA100 






Reverse mutation S. typhimurium TA1535, TA100, 
TA1537, TA1538, TA98 
0.1–1000 µg/ml Negativea,b (McMahon et al., 1979) 
Reverse mutation S. typhimurium TA100, TA98, 
TA1535 





(Loquet et al., 1981) 
Reverse mutation S. typhimurium TA100, TA98, 
TA102 
Up to 115 320 µg/plate Negativea,b (Aeschbacher et al., 1989) 
Reverse mutation S. typhimurium TA100, TA98 15–63 µg/plate Negativea,b (Shinohara et al., 1986) 
Reverse mutation S. typhimurium TA104 5–500 µg/plate Positiveb (Shane et al., 1988) 
Reverse mutation S. typhimurium TA100, TA102  5–500 µg/plate Negativeb (Shane et al., 1988) 
Reverse mutation S. typhimurium TA104, TA102 96 µg/plate Negative (Marnett et al., 1985a) 
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Table 4: Summary of genotoxicity data of furfuryl derivatives evaluated by JECFA (JECFA, 2001b) 
FL-no 
JECFA-no 
EU Register name 
JECFA name 
Structural formula End-point Test system Concentration Results Reference 
Reverse mutation S. typhimurium TA98, TA100, 
TA1535 






Reverse mutation S. typhimurium TA98, TA100 Up to 1000 µg Negativea (Osawa & Namiki, 1982) 
Reverse mutation S. typhimurium TA98, TA100, 
TA1535, TA1537  




Reverse mutation S. typhimurium TA100  8000 µg/plate Positivea,b (Zdzienicka et al., 1978) 
Reverse mutation  S. typhimurium TA98 8000 µg/plate Negativea,b (Zdzienicka et al., 1978) 
Reverse mutation S. typhimurium TA100, TA102 100–10 000 µg/plate Negativea (Dillon et al., 1998) 
Reverse mutation S. typhimurium TA104 100–10 000 µg/plate Equivocala (Dillon et al., 1998) 
Reverse mutation S. typhimurium TA102, TA104 100–10 000 µg/plate Negativeb (Dillon et al., 1998) 
Reverse mutation S. typhimurium TA100 100–10 000 µg/plate Equivocalb (Dillon et al., 1998) 
Reverse mutation S. typhimurium TA100 (modified 
assay) 
426 µg/plate Negativea,b (Kim et al., 1987b) 
Reverse mutation S. typhimurium TA100, TA1535, 
TA1537 (modified assay) 
200 000 µg/ml Negative (McGregor et al., 1981) 
Reverse mutation E. coli WP2, WP2 uvrA (modified 
assay) 
0.1–1000 µg/ml Negativea,b (McMahon et al., 1979) 
SOS induction  S. typhimurium TA1535/ pSK1002 1932 µg/ml Negativea,b (Nakamura et al., 1987) 
DNA repair B. subtilis H17 (rec+) and M45 
(rec–) 
Up to 1000 µg Negativea (Osawa & Namiki, 1982) 
DNA repair B. subtilis H17 (rec+) and M45 
(rec–) 
0.6 ml Negativea,b (Matsui et al., 1989) 
DNA repair B. subtilis H17 (rec+) and M45 
(rec–) 
1700–17 000 µg/disc Positivea,b (Shinohara et al., 1986) 






(McGregor et al., 1988b) 
Sister chromatid exchange Chinese hamster ovary cells 2500–4000 µg/ml Positivea,b (Stich et al., 1981b) 
Sister chromatid exchange Chinese hamster ovary cells Up to 1170 µg/ml Positivea,b (NTP, 1990a) 
Sister chromatid exchange Human lymphocytes Up to 0.035 mmol/La 
0.07– 0.14 mmol/Lc 
Negativea,b 
Positivea,b 
(Gomez-Arroyo & Souza, 
1985) 




(Nishi et al., 1989) 
Chromosomal aberration Chinese hamster ovary cells Up to  40 mmol/L  (3840 mg) Positivea,b (Stich et al., 1981b) 
Chromosomal aberration Chinese hamster ovary cells 3000 µg/ml Positive (Stich et al., 1981a) 
Chromosomal aberration Chinese hamster ovary cells Up to 1230 µg/ml Positivea,b (NTP, 1990a) 
Unscheduled DNA synthesis Human liver slices 0.005–10 mmol/L  Negative (Adams et al., 1998b) 
Sex-linked recessive lethal mutation D. melanogaster 1000 mg/kg of diet Negative (Woodruff et al., 1985) 
Sex-linked recessive lethal mutation D. melanogaster 100 mg/kg by injection Positive (Woodruff et al., 1985) 
Sex-linked recessive lethal mutation D. melanogaster Up to 6500 mg/kg by injection Negative (Rodriquez-Arnaiz et al., 
1989) 
Chromosomal loss D. melanogaster Oral or injected dose of 3750–
5000 mg/kg of diet. Mated 
with repair-proficient females 
Negative (Rodriquez-Arnaiz et al., 
1992) 
Chromosomal loss D. melanogaster Oral or injected dose of 3750–
5000 mg/kg of diet. Mated 
Positive (Rodriquez-Arnaiz et al., 
1992) 
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Table 4: Summary of genotoxicity data of furfuryl derivatives evaluated by JECFA (JECFA, 2001b) 
FL-no 
JECFA-no 
EU Register name 
JECFA name 
Structural formula End-point Test system Concentration Results Reference 
with repair-deficient females 






Sister chromatid exchange Mouse bone-marrow cells 50–200 mg/kg bw by injection Negative (NTP, 1990a) 
Spermhead abnormalities Mice 4000 mg/kg of diet daily for 5 
weeks 
Negative (Subramanyam et al., 1989) 
Somatic chromosomal mutation  Swiss albino mouse bonemarrow 
cells 
1000–2000 mg/kg of diet 
4000 mg/kg bw for 5 days 
Negative 
Positive 
(Subramanyam et al., 1989) 
Sister chromatid exchange Adult human lymphocytes 9454 mg/m3 in occupational 
atmosphere 
Negative (Gomez-Arroyo & Souza, 
1985) 
Chromosomal aberration Adult human lymphocytes 9454 mg/m3in occupational 
atmosphere 
Negative (Gomez-Arroyo & Souza, 
1985) 
Unscheduled DNA synthesis B6C3F1 mice  50–320 mg/kg bw orally Negative (Edwards, 1999) 
Unscheduled DNA synthesis Fischer 344 rats 5–50 mg/kg bw orally Negative (Phillips et al., 1997) 
Reverse mutation S. typhimurium TA1537, TA100, 
TA1535 








Reverse mutation S. typhimurium TA98, TA100, 
TA102  
96,100 µg/plate Negativea,b (Aeschbacher et al., 1989) 
Reverse mutation S. typhimurium TA98, TA100 79–316 µg/plate Negativea,b (Shinohara et al., 1986) 
DNA repair B. subtilis H17 (rec+) and M45 
(rec–) 
0.55–5500 µg/disk Positivea,b (Shinohara et al., 1986) 
Sister chromatid exchange Chinese hamster ovary cells 2200–4070 µg/ml Positivea,b (Stich et al., 1981b) 
NR=Not Reported. 
1With and without S9 metabolic activation.  
2 Without S9 metabolic activation.  
3 With S9 metabolic activation. 
4 Concentration that was added to the culture. 
5 Significant increases in % DNA-protein cross-links occurred only when cell viability was 40 % or less (i.e. high incidence of cell death). 
6 TA98 with S9 metabolic activation; TA100 without S9 metabolic activation. 
7 5-Hydroxymethylfurfuraldehyde with 0.05 mol L-tryptophan without the presence of nitrite treatment.  
8 5-Hydroxymethylfurfuraldehyde with 0.05 mol L-tryptophan treated with nitrite.  
9 At concentrations of 12 mmol and greater, positive results were obtained without S9 metabolic activation. The dose dependent results were noted at concentrations known to be cytotoxic.  
10 Metabolic activation not reported.  
11 Effects occurred at concentrations inhibiting cellular growth. 
12 Dose levels above 300 microgram/ml were cytotoxic.  
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TABLE 5: GENOTOXICITY OF FURFURAL, SCF OPINION ON FURFURAL AND FURFURAL DIETHYLACETAL (SCF, 2003A) 
 
Table 5: Genotoxicity on Furfural, SCF Opinion on Furfural and Furfuraldiethylacetal (SCF, 2003a) 
Substance End-point Test object Concentration Result Reference 
In vitro 
Furfural Reverse mutation S.typhimurium TA100, TA98, TA1535 0.05-60 μmol/plate Weakly positive (TA100)b (Loquet et al., 1981) 
S.typhimurium TA100, TA98, TA102 ≤1.2 mmol/plate Negativea (Aeschbacher et al., 1989) 
S.typhimurium TA100, TA98 0.165-0.660 μmol/plate Negativea (Shinohara et al., 1986) 
S.typhimurium TA102, TA104 5-500 μg/plate Positive (TA104) (Shane et al., 1988) 
S.typhimurium TA98, TA100,TA1535, TA1537 33.3-6666 μmol/plate Negativea (Mortelmans et al., 1986) 
S.typhimurium TA98, TA100 1-15 μL/plate Positivea (TA100) (Zdzienicka et al., 1978) 
S.typhimurium TA98, TA100 7 μL/plate Negativea (Sasaki & Endo, 1978) 
S.typhimurium TA100 4.44 μmol/plate Negativea (Osawa & Namiki, 1982) 
S.typhimurium TA98, TA100, TA104, 
E.coliWP2uvrA/PKM101 
20 μL/plate Negativea (McMahon et al., 1979) 
S.typhimurium TA104 1 μmol (max. non-toxic dose) Negativeb (Marnett et al., 1985a) 
Umu gene expression S.typhimurium TA1535/pSK/002 1932 μg/mL Negativea (Nakamura et al., 1987) 
Rec assay B.subtilis H17, M45 1.7-17 mg/disk Positivea (Shinohara et al., 1986) 
B.subtilis H17, M45 1 mg/disk Negativea (Matsui et al., 1989) 
Forward mutation L5178Ytk+/- mouse lymphoma cells 25-800 μg/mL Positiveb (McGregor et al., 1988b) 
Chromosomal aberration Chinese hamster ovary cells 10-40 mM Positivea (Stich et al., 1981a; Stich et al., 1981b) 
Chinese hamster ovary cells 200-1230 μg/mL Positivea (Galloway et al., 1985) 
Chinese hamster ovary cells 1.5-5000 μg/mL Positivea (Gudi & Schadly, 1996) 
Chinese hamster V79 cells 500-2000 μg/mL Positivea (Nishi et al., 1989) 
Sister chromatid exchange Chinese hamster ovary cells 11.7-3890 μg/mL Positivea (Galloway et al., 1985) 
Human peripheral lymphocytes 3.5-14x10-5 M Positiveb (Gomez-Arroyo & Souza, 1985) 
Unscheduled DNA synthesis Human liver slices 0.14 mmol/L 
0-25 mmol/L 
Negative (Lake, 1998) 
In vivo 
 Furfural Sex-linked recessive lethal 
mutation 
D.melanogaster 1000 ppm, in diet Negative (Woodruff et al., 1985) 
D.melanogaster 100 ppm, by injection Positive (Woodruff et al., 1985) 
Wing spot test D.melanogaster 3750-7500 ppm by aerial exposure Positive (Rodriquez-Arnaiz et al., 1989) 
Sex-chromosome loss D.melanogaster 3750-5000 ppm, in diet and by 
injection 
Positive on injection (Rodriquez-Arnaiz et al., 1989; 
Rodriquez-Arnaiz et al., 1992) 
Reciprocal translocation D.melanogaster 1000 ppm, in diet Negative (Woodruff et al., 1985) 
Sister chromatid exchange/ 
chromosomal aberration 
B6C3F1 mouse bone marrow cells 50-200 mg/kg bw, once i.p. Negative (NTP, 1990a) 
Somatic chromosomal aberration Swiss albino mouse bone marrow cells 4000 ppm for 5 days, in diet Negative (Subramanyam et al., 1989)+ 
Spermhead abnormalities Swiss albino mouse 4000 ppm for 5 weeks, in diet Negative (Subramanyam et al., 1989)+ 
 Unscheduled DNA synthesis Fischer 344 rat hepatocytes 5.0, 16.7 or 50 mg/kg bw, orally Negative (Phillips et al., 1997) 
B6C3F1 mouse hepatocytes 50, 175 or 320 mg/kg bw, orally Negative (Edwards, 1999) 
a With and without metabolic activation. 
a Without metabolic activation. 
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c With metabolic activation. 
+ Abstract only; no details available. 
 
TABLE 6: SUMMARY OF ADDITIONAL GENOTOXICITY DATA CONSIDERED BY EFSA (EFSA, 2004C) 
 
Table 6: GENOTOXICITY (in vivo) (EFSA, 2004c) 
Chemical Name [FL-no]  Test System Test Object  Route Dose Result  Reference  Comments 
Furfural [13.018] Gene mutation λlacZ CD2F1(BALB/c x DBA/2 Gavage 0, 75, 150, 300 mg/kg bw/d No increase in λlacZ gene 
mutation in liver DNA 
(CIVO-TNO, 2003) This study is considered valid. 
TABLE 7: SUMMARY OF ADDITIONAL GENOTOXICITY DATA ON 5-HMF (IN VITRO) 
 
Table 7: Summary of Additional Genotoxicity data on 5-hydroxymethylfurfural (in vitro) 
Chemical name [Fl.-no.] Test system Test object Concentration Result Reference 
5-Hydroxymethylfurfural [13.139] Ames S. typhimurium TA97, TA98, TA102, TA1535 100-10,000 µg/plate Negative1 (NTP, 2008b) 
Ames S. typhimurium TA100 100-10,000 µg/plate Weakly positive2 (NTP, 2008b) 
Ames S. typhimurium TA100 and TA98 1,500-10,000 µg/plate Negative1 (NTP, 2008b) 
Ames S. typhimurium TA98, TA100, TA1535, 
TA1537 
at 0.5 µg/mL up to 5000 µg/mL Negative1 (Severin et al., 2010) 
Reverse mutation E. coli WP2 uvrA/pKM101 1,500-10,000 µg/plate Negative1 (NTP, 2008b) 
Micronucleus assay HepG2 cells 0, 5.35, 7.87, 11.57, 17, 25, 36.6 mM Negative6 (Severin et al., 2010) 
SCE induction V79-hCYP2E1-hSULT1A1 cells 19.8–3808 µM Positive (Glatt et al., 2005) 
SCE induction V79-Mz cells 238 - 3808 µM, Positive7  (Glatt et al., 2005) 
Comet Assay HepG2 cells 0, 5.35, 7.87, 11.57, 17, 25, 36.6 mM Positive5, 6 (Severin et al., 2010) 
Comet Assay Human Caco-2 cells 3,153-12,611 µg/mL (25-100 mM) Positive3 (Durling et al., 2009) 
Comet Assay Human HEK293 cells 3,153-12,611 µg/mL (25-100 mM) Positive3 (Durling et al., 2009) 
Comet Assay Mouse lymphoma L5178Y cells 3,153-12,611 µg/mL (25-100 mM) Positive3 (Durling et al., 2009) 
Comet Assay Chinese hamster V-79  cells 315-12,611 µg/mL (2.5-100 mM) Positive4 (Durling et al., 2009) 
Comet Assay Chinese hamster V-79-hP-PST cells 315-12,611 µg/mL (2.5-100 mM) Positive4 (Durling et al., 2009) 
Micronucleus assay Mouse peripheral blood cells 47, 94, 188, 375 or 750 mg/kg bw/day Negative (NTP, 2008b) 
1 With and without S9 metabolic activation. 
2 Without S9 metabolic activation. 
3 Positive only at the highest concentration tested with significant decrease in cell viability. 
4 Positive at high concentration with significantly reduced cell viability. 
5 Cytotoxic at the two highest doses. 
6 20 hours of exposure. 
7 Weakly positive but statistically significant at each concentration. 
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TABLE 8: SUMMARY OF ADDITIONAL GENOTOXICITY DATA ON 5-HMF (IN VIVO) 
 
Table 8: Summary of Additional Genotoxicity data on 5-hydroxymethylfurfural (in vivo) 
Chemical name [Fl.-no.] Test system Test object Route Concentration Result Reference EFSA Comments 
5-Hydroxymethylfurfural [13.139] Micronucleus assay Mouse peripheral blood cells Gavage 47, 94, 188, 375 or 750 mg/kg bw/d Negative (NTP, 2008b) 3-months micronucleus assay. 
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Abbreviations 
ADI  Acceptable Daily Intake 
BW  Body Weight 
CAS  Chemical Abstract Service 
CEF Panel on Food Contact Materials, Enzymes, Flavourings and Processing Aids 
Chemical Abstract Service 
CHO  Chinese hamster ovary (cells) 
CoE  Council of Europe 
DNA  Deoxyribonucleic acid 
EC European Commission 
EFFA  European Flavour and Fragrance Association 
EFSA  European Food Safety Authority 
ENU  Ethylnitrosourea 
EU  European Union 
FAO  Food and Agriculture Organization of the United Nations  
FEMA  Flavor and Extract Manufacturers Association 
FGE  Flavouring Group Evaluation  
FLAVIS (FL) Flavour Information System (database) 
GLP  Good Laboratory Practice 
HMF  Hydroxymethylfurfural  
ID   Identity 
IOFI  International Organization of the Flavour Industry 
IR   Infrared spectroscopy 
JECFA  The Joint FAO/WHO Expert Committee on Food Additives 
LD50  Lethal Dose, 50 %; Median lethal dose 
MF  Methylfurfural 
MS  Mass spectrometry 
MSDI  Maximised Survey-derived Daily Intake 
mTAMDI Modified Theoretical Added Maximum Daily Intake 
NAD  Nicotinamide Adenine Dinucleotide  
NADP  Nicotinamide Adenine Dinucleotide Phosphate 
NCE  Normochromatic erythrocytes 
No  Number 
NOAEL No Observed Adverse Effect Level 
NOEL  No Observed Effect Level 
NTP  National Toxicology Program 
OECD  Organisation for Economic Co-operation and Development 
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PAPS  3'-Phosphoadenosine-5'-phosphosulphate 
PCE  Polychromatic erythrocytes 
PFU  Plaque-forming units 
SCE  Sister Chromatid Exchange 
SCF  Scientific Committee on Food 
SMART  Somatic Mutation and Recombination Test  
SMF  5-Sulphoxy-methylfurfural 
SULT  Sulphotransferases 
TAMDI Theoretical Added Maximum Daily Intake 
UDS  Unscheduled DNA Synthesis  
WHO  World Health Organisation  
